IVIG Trial for the Treatment of Bronchopulmonary Dysplasia
Status:
RECRUITING
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
It is intended to examine the efficacy and safety of intravenous immunoglobulin(IVIG) for the bronchopulmonary dysplasia in preterms. Participants will received continuous infusion IVIG 1 g/kg/day for the first 2 days, 0.5 g/kg/day for next 3 days (total does 3.5 g/kg), repeatable 1\~2 times if necessary (5 days after the last infusion).
Phase:
PHASE2
Details
Lead Sponsor:
International Peace Maternity and Child Health Hospital